2012年8月20日 訊 /生物谷BIOON/ --在一項新研究中,，研究人員發(fā)現(xiàn)B型流感病毒高度保守性的抗原表位，為流感的防治帶來新的希望,。
在這項研究中,，研究人員發(fā)現(xiàn)廣泛性中和B型流感病毒的抗體，為研發(fā)基于流感單克隆抗體的免疫療法和"萬能"流感疫苗帶來了希望,。然而,，每年流感疫情當中大多數(shù)，是由兩種共同傳播的但抗原性不同的B型流感病毒造成的,。
當前的這項研究發(fā)現(xiàn)人類單克隆抗體：CR8033,，CR8071，CR9114,，可保護小鼠免受上述兩種致命性B型流感病毒的傷害,。CR8033和CR8071抗體識別B型流感病毒血凝素（HA）頭部區(qū)域不同的保守性抗原表位，而CR9114結合一個位于HA莖部的保守性抗原表位,，從而防止流感A和B型流感病毒對機體的致命毒害,。
這些抗體可能預示著，人們在開發(fā)基于單克隆抗體的流感治療方法和針對所有A和B型流感病毒的通用流感疫苗方面取得重大進展,。（生物谷bioon.com）
doi:10.1016/j.cell.2011.10.017
PMC:
PMID:
Highly Conserved Protective Epitopes on Influenza B Viruses
Cyrille Dreyfus1,*,Nick S. Laursen1,2,*,Ted Kwaks3,David Zuijdgeest3,Reza Khayat1,Damian C. Ekiert1,?,Jeong Hyun Lee1,Zoltan Metlagel1,?,Miriam V. Bujny3,Mandy Jongeneelen3,Remko van der Vlugt3,Mohammed Lamrani3,Hans J. W. M. Korse3,Eric Geelen3,?zcan Sahin3,Martijn Sieuwerts3,Just P. J. Brakenhoff3,Ronald Vogels3,Olive T. W. Li4,Leo L. M. Poon4,Malik Peiris4,Wouter Koudstaal3,Andrew B. Ward1,Ian A. Wilson1,5,§,Jaap Goudsmit3,§,Robert H. E. Friesen
Identification of broadly neutralizing antibodies against influenza A viruses has raised hopes for the development of monoclonal antibody–based immunotherapy and “universal” vaccines for influenza. However, a significant part of the annual flu burden is caused by two cocirculating, antigenically distinct lineages of influenza B viruses. Here, we report human monoclonal antibodies, CR8033, CR8071, and CR9114, that protect mice against lethal challenge from both lineages. Antibodies CR8033 and CR8071 recognize distinct conserved epitopes in the head region of the influenza B hemagglutinin (HA), whereas CR9114 binds a conserved epitope in the HA stem and protects against lethal challenge with influenza A and B viruses. These antibodies may inform on development of monoclonal antibody–based treatments and a universal flu vaccine for all influenza A and B viruses.
